Pfizer (PFE) Research & Development (2009 - 2026)

Pfizer (PFE) has 18 years of Research & Development data on file, last reported at $2.5 billion in Q1 2026.

• Quarterly Research & Development rose 13.03% year-over-year to $2.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 billion (up 7.35% YoY) and the FY2025 annual result came in at $10.4 billion, down 3.56% from the prior year.
• Research & Development eased to $2.5 billion in Q1 2026 per PFE's latest filing, from $3.2 billion in the prior quarter.
• Across five years, Research & Development topped out at $3.2 billion in Q4 2025 and bottomed at $2.2 billion in Q1 2025.
• The 5-year median for Research & Development is $2.6 billion (2024), against an average of $2.6 billion.
• The widest annual swing landed in 2022, when Research & Development gained 25.73%; it then slipped 11.63% in 2025.
• Tracing PFE's Research & Development over 5 years: stood at $2.7 billion in 2022, then increased by 4.41% to $2.8 billion in 2023, then dropped by 7.71% to $2.6 billion in 2024, then climbed by 23.4% to $3.2 billion in 2025, then fell by 22.33% to $2.5 billion in 2026.
• Per Business Quant, the three latest PFE Research & Development figures stand at $2.5 billion (Q1 2026), $3.2 billion (Q4 2025), and $2.5 billion (Q3 2025).

Peer Comparison